PCSK9 and familial hypercholesterolemia: Due to the absence of head‐to‐head trials between these four agents, this study is aimed at comprehensively assessing the efficacy and safety of four novel PCSK9 monoclonal antibodies in the treatment of hypercholesterolemia employing network meta‐analysis (NMA) by integrating direct and indirect evidence in dosage levels.